There are a host of barriers to realizing the promise of personalized medicine -- insurance reimbursement, privacy and regulatory issues, information and aggregation issues, among others -- but perhaps none so pernicious as resistance.
In an ideal world, all funds would take advantage of the technology advances in the administration industry surrounding data aggregation and the dissemination of Form PF and allow administrators to directly distribute certain information to third party data providers for investors to access in analytical software platforms.